ClinicalTrials.gg
CompletedNCT01545440Updated Mar 5, 2015

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

A Phase 2 interventional study of lebrikizumab and lebrikizumab in Asthma, sponsored by Genentech, Inc.. Completed at 71 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
5th of 12
258 · median 224
Started
2012
with 1 other
Phase 2
7 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
5 of 12
Genentech, Inc.

Among the 12 studies testing lebrikizumab in Asthma, this one is the 5th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 4th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18 to 75 years of age at Visit 1
  • Asthma diagnosis for >/= 12 months prior to the start of screening (Visit 1)
  • Bronchodilator response during screening
  • Pre-bronchodilator 40%-80% of predicted during screening
  • On ICS (inhaled ) 500-2000 mcg/day of fluticasone propionate DPI or equivalent for >/= 6 months prior to the start of screening (Visit 1) with no anticipated changes throughout the study
  • On an eligible second controller medication (LABA, LAMA, LTRA or theophylline within the prescribed dosing range)
  • Uncontrolled asthma as defined by protocol both during screening period and at time of randomization
  • Chest X-ray or computed tomography (CT) scan obtained within 12 months prior to screening or chest X-ray during screening period confirming the absence of other lung disease
  • Demonstrated adherence with controller medication during the screening period

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Use of zileuton or roflumilast within 6 months prior to screening
  • Maintenance oral therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1
  • Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1
  • Major episode of infection within 4 weeks prior to Visit 1 or treatment with oral antibiotics within 2 weeks prior to Visit 1
  • Active parasitic infection within the 6 months prior to Visit 1
  • Active tuberculosis requiring treatment within the 12 months prior to Visit 1
  • Known immunodeficiency, including, but not limited to, infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • History of cystic fibrosis, , and/or other lung disease other than asthma
  • Known or current evaluation for a potential malignancy
  • Current smoker or former smoker with a history >10 pack years
  • History of alcohol, drug or chemical abuse
  • Initiation or change in allergen immunotherapy within 3 months prior to Visit 1
  • Use of biologic therapy including omalizumab during 6 months prior to Visit 1
  • Receipt of live/attenuated vaccine within 4 weeks prior to Visit 1
  • Pregnant or lactating women
  • (BMI) > 38 kg/m2
  • Body weight \< 40 kg
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    lebrikizumab - highest dose

    Drug: lebrikizumab

  • Experimental
    lebrikizumab - lowest dose

    Drug: lebrikizumab

  • Experimental
    lebrikizumab - middle dose

    Drug: lebrikizumab

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • subcutaneous dose every 4 weeks

  • subcutaneous dose every 4 weeks

  • subcutaneous dose every 4 weeks

  • Drugplacebo

    subcutaneous dose every 4 weeks

06

What researchers measure

Primary outcomes

  1. Rate of asthma exacerbations during the 52-week placebo-controlled period

    Time frame: weeks 0-52

Secondary outcomes

  1. Change in lung function: pre-bronchodilator FEV1

    Time frame: from baseline to week 52

  2. Time to first asthma exacerbation

    Time frame: from baseline to week 52

  3. Change in fractional exhaled nitric oxide (FeNO)

    Time frame: from baseline to week 52

  4. Change in asthma-specific health-related quality of life, assessed by the Standardized Asthma Quality of Life Questionnaire (AQLQ[S])

    Time frame: from baseline to week 52

  5. Change in asthma rescue medication use

    Time frame: from baseline to week 52

  6. Rate of urgent asthma-related health care utilization during the 52-week placebo-controlled period

    Time frame: from baseline to week 52

07

Study locations

71 sites
  • Pell City, Alabama 35128, United States
  • Scottsdale, Arizona 85251, United States
  • Scottsdale, Arizona 85266, United States
  • Tucson, Arizona 85712, United States
  • Bakersfield, California 93301, United States
  • Fountain Valley, California 92708, United States
  • Fullerton, California 92835, United States
  • Los Angeles, California 90025, United States
  • Los Angeles, California 90048, United States
  • Mission Viejo, California 92691, United States
  • Napa, California 94558, United States
  • Orange, California 92868, United States
  • Rancho Mirage, California 92270, United States
  • Sacramento, California 95819, United States
  • San Diego, California 92108, United States
  • Studio City, California 91607, United States
  • Upland, California 91786, United States
  • Walnut Creek, California 94598, United States
  • Centennial, Colorado 80112, United States
  • Colorado Springs, Colorado 80907, United States
  • Denver, Colorado 80206, United States
  • Wheat Ridge, Colorado 80033, United States
  • Waterbury, Connecticut 06708, United States
  • Gainesville, Florida 32605, United States
  • North Palm Beach, Florida 33408, United States
  • Ocala, Florida 34471, United States
  • Tallahassee, Florida 32308, United States
  • Tampa, Florida 33613, United States
  • Winter Park, Florida 32789, United States
  • Albany, Georgia 31707, United States
  • Savannah, Georgia 31406, United States
  • Honolulu, Hawaii 96814, United States
  • River Forest, Illinois 60305, United States
  • Topeka, Kansas 66606, United States
  • Metairie, Louisiana 70006, United States
  • Bangor, Maine 04401, United States
  • Kansas City, Missouri 64114, United States
  • Bellevue, Nebraska 68123, United States
  • Las Vegas, Nevada 89106, United States
  • Las Vegas, Nevada 89119, United States
  • Albuquerque, New Mexico 87131, United States
  • Bronx, New York 10461, United States
  • Great Neck, New York 11021, United States
  • New York, New York 10016, United States
  • Rockville Centre, New York 11570, United States
  • High Point, North Carolina 27262, United States
  • Wilmington, North Carolina 28401, United States
  • Cincinnati, Ohio 45231, United States
  • Eugene, Oregon 97401-7721, United States
  • Lake Oswego, Oregon 97035, United States
  • Portland, Oregon 97202, United States
  • Blue Bell, Pennsylvania 19422, United States
  • Easton, Pennsylvania 18045, United States
  • Harrisburg, Pennsylvania 17110, United States
  • Philadelphia, Pennsylvania 19115, United States
  • Upland, Pennsylvania 19013, United States
  • Warwick, Rhode Island 02865, United States
  • Greenville, South Carolina 29607, United States
  • Spartanburg, South Carolina 29303, United States
  • Knoxville, Tennessee 37909, United States
  • Arlington, Texas 76018, United States
  • Dallas, Texas 75230, United States
  • El Paso, Texas 79925, United States
  • Fort worth, Texas 76109, United States
  • McKinney, Texas 75069, United States
  • San Antonio, Texas 78224, United States
  • San Antonio, Texas 78251, United States
  • Henrico, Virginia 23233, United States
  • Seattle, Washington 98105, United States
  • Madison, Wisconsin 53792, United States
  • Nedlands, Western Australia 6009, Australia
08

References and documents

Publications

  • Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7. PubMed 33217063 ↗
  • Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22. PubMed 26001563 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Mar 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2012
First posted
Mar 6, 2012
Start
Mar 2012
Primary completionActual
Mar 2013
CompletionActual
Jul 2013
Last update
Mar 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01545440
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 6, 2012
Start date
Mar 2012
Primary completion
Mar 2013
Completion
Jul 2013
Last update
Mar 5, 2015

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion